Literature DB >> 3830700

Some reactions and properties of nitro radical-anions important in biology and medicine.

P Wardman.   

Abstract

Nitroaromatic compounds, ArNO2 have widespread actual or potential use in medicine and cancer therapy. There is direct proof that free-radical metabolites are involved in many applications, and an appreciation of the conceptual basis for their therapeutic differential; however, an understanding of the detailed mechanisms involved is lacking. Redox properties control most biological responses of nitro compounds, and the characteristics of the one-electron couple: ArNO2/ArNO2- are detailed. The "futile metabolism" of nitroaryl compounds characteristic of most aerobic nitroreductase systems reflects competition between natural radical-decay pathways and a one-electron transfer reaction to yield superoxide ion, O2-. Prototropic properties control the rate of radical decay, and redox properties control the rate of electron transfer to O2 or other acceptors. There are clear parallels in the chemistry of ArNO2- and O2-. While nitro radicals have frequently been invoked as damaging species, they are very unreactive (except as simple reductants). It seems likely that reductive metabolism of nitroaryl compounds, although generally involving nitro radical-anions as obligate intermediates (and this is required for therapeutic selectivity towards anaerobes), results in biological damage via reductive metabolites of higher reduction order than the one-electron product.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3830700      PMCID: PMC1568617          DOI: 10.1289/ehp.8564309

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  53 in total

1.  Hypoxia-enhanced reduction and covalent binding of [2-3H]misonidazole in the perfused rat liver.

Authors:  B R Smith
Journal:  Biochem Pharmacol       Date:  1984-04-15       Impact factor: 5.858

2.  Chemical modifiers of cancer treatment. Part 1. Banff, Canada, 27 November-1 December, 1983.

Authors: 
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-08       Impact factor: 7.038

3.  Detection of a reactive metabolite of misonidazole in hypoxic mammalian cells.

Authors:  A J Varghese; G F Whitmore
Journal:  Radiat Res       Date:  1984-02       Impact factor: 2.841

Review 4.  Oxygen toxicity, oxygen radicals, transition metals and disease.

Authors:  B Halliwell; J M Gutteridge
Journal:  Biochem J       Date:  1984-04-01       Impact factor: 3.857

5.  Cis-trans isomerization of the (5-nitro-2-furyl)acrylamide, AF-2, initiated by ascorbate, glutathione, Fe(II) and OH-.

Authors:  E D Clarke; P Wardman; I Wilson
Journal:  Biochem Pharmacol       Date:  1984-01-01       Impact factor: 5.858

6.  2-Hydroxylaminoimidazoles--unstable intermediates in the reduction of 2-nitroimidazoles.

Authors:  R A McClelland; J R Fuller; N E Seaman; A M Rauth; R Battistella
Journal:  Biochem Pharmacol       Date:  1984-01-15       Impact factor: 5.858

7.  Reductive metabolism and activation of benznidazole.

Authors:  M Masana; E G de Toranzo; J A Castro
Journal:  Biochem Pharmacol       Date:  1984-04-01       Impact factor: 5.858

8.  Glutathione conjugates of misonidazole.

Authors:  A J Varghese
Journal:  Biochem Biophys Res Commun       Date:  1983-05-16       Impact factor: 3.575

9.  Distinct reduction of nitrofurans and metronidazole to free radical metabolites by Tritrichomonas foetus hydrogenosomal and cytosolic enzymes.

Authors:  S N Moreno; R P Mason; R Docampo
Journal:  J Biol Chem       Date:  1984-07-10       Impact factor: 5.157

10.  Generation of free radicals from metronidazole and other nitroimidazoles by Tritrichomonas foetus.

Authors:  S N Moreno; R P Mason; R P Muniz; F S Cruz; R Docampo
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

View more
  20 in total

Review 1.  Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes.

Authors:  Peter Wardman
Journal:  Br J Radiol       Date:  2018-03-20       Impact factor: 3.039

2.  Reactivity of nitro-thiophene derivatives with electron and oxygen radicals studied by pulse radiolysis and polarographic techniques.

Authors:  A Breccia; F Busi; E Gattavecchia; M Tamba
Journal:  Radiat Environ Biophys       Date:  1990       Impact factor: 1.925

3.  Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation.

Authors:  Belinda S Hall; Shane R Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

4.  Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs.

Authors:  Liam J O'Connor; Cindy Cazares-Körner; Jaideep Saha; Charles N G Evans; Michael R L Stratford; Ester M Hammond; Stuart J Conway
Journal:  Nat Protoc       Date:  2016-03-24       Impact factor: 13.491

5.  Design of a hypoxia-activated prodrug inhibitor of O6-alkylguanine-DNA alkyltransferase.

Authors:  Rui Zhu; Helen A Seow; Raymond P Baumann; Kimiko Ishiguro; Philip G Penketh; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  Bioorg Med Chem Lett       Date:  2012-08-10       Impact factor: 2.823

6.  A strategy for selective O(6)-alkylguanine-DNA alkyltransferase depletion under hypoxic conditions.

Authors:  Philip G Penketh; Krishnamurthy Shyam; Raymond P Baumann; Kimiko Ishiguro; Eric V Patridge; Rui Zhu; Alan C Sartorelli
Journal:  Chem Biol Drug Des       Date:  2012-05-23       Impact factor: 2.817

7.  Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline).

Authors:  Hongchao Jiang; Jori E Taggart; Xiaoxi Zhang; Doris M Benbrook; Stuart E Lind; Wei-Qun Ding
Journal:  Cancer Lett       Date:  2011-07-06       Impact factor: 8.679

8.  Low-Energy Electron Induced Reactions in Metronidazole at Different Solvation Conditions.

Authors:  Christine Lochmann; Thomas F M Luxford; Samanta Makurat; Andriy Pysanenko; Jaroslav Kočišek; Janusz Rak; Stephan Denifl
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-02

9.  The trypanocidal benznidazole promotes adaptive response to oxidative injury: Involvement of the nuclear factor-erythroid 2-related factor-2 (Nrf2) and multidrug resistance associated protein 2 (MRP2).

Authors:  Juan Pablo Rigalli; Virginia Gabriela Perdomo; Nadia Ciriaci; Daniel Eleazar Antonio Francés; María Teresa Ronco; Amy Michele Bataille; Carolina Inés Ghanem; María Laura Ruiz; José Enrique Manautou; Viviana Alicia Catania
Journal:  Toxicol Appl Pharmacol       Date:  2016-05-12       Impact factor: 4.219

10.  Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects.

Authors:  Taslim A Al-Hilal; Mohammad Anwar Hossain; Ahmed Alobaida; Farzana Alam; Ali Keshavarz; Eva Nozik-Grayck; Kurt R Stenmark; Nadezhda A German; Fakhrul Ahsan
Journal:  J Control Release       Date:  2021-04-26       Impact factor: 11.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.